News | June 23, 2021
Vaishali Pharma bags $100,000 order from Russia
The company has predominantly built a portfolio into veterinary products
The company has predominantly built a portfolio into veterinary products
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The company plans to enter the EU markets in FY22
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
India sales grew 23.5% YoY with consolidation of Wockhardt products
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
